Lumito gained valuable visibility through a presentation by Professor Paul Waring at Akoya’s Spotlight Theatre, where he introduced Lumito’s SCIZYS platform and nanoparticle technology as a next-generation solution for precise and accurate biomarker quantification in tissue. Our presence at AACR strategically positions Lumito at the evolving diagnostic landscape, aligning with the future of targeted therapy development and cutting-edge research advancements.

“With the recent FDA approval of trastuzumab deruxtecan (Enhertu) for patients with advanced HR-positive, HER2-negative breast cancer, including those with low or ultralow HER2 expression, we’re entering a new era of precision oncology," said Professor Paul Waring during his presentation at AACR in Chicago. "However, this shift brings a major challenge for pathologists: accurately quantifying HER2 expression at these very low levels using traditional DAB-based immunohistochemistry. The variability in detecting IHC 0, 1+, or 2+ makes it difficult to consistently determine which patients are truly eligible for Enhertu. What we urgently need are membrane-targeted solutions that offer greater accuracy and precision at the low and ultralow end of HER2 expression, similar to how HER2 FISH is used for ambiguous 2+ cases. I introduced Akoya’s multiplex mIF breast cancer panel and stressed the importance of calibrating and orthogonally validating these results using highly sensitive, photostable, and autofluorescence-free technologies, like Lumito’s unconverted nanoparticles and SCIZYS detection system. These advanced platforms have the potential to bring much-needed clarity to HER2 testing and improve patient selection for emerging targeted therapies."

“We’re very pleased and grateful to have Professor Paul Waring as both an advisor and advocate for our technology,” said Sanna Wallenborg, CEO of Lumito. “Paul brings deep insight into the drug development landscape and continually helps us refine our offering and strategic focus. He truly understands the challenges that come with introducing more targeted and potent therapies to market, and how SCIZYS and our nanoparticle-based platform can help meet that critical need.”